


That which is claimed is:

1. Use of a therapeutically effective amount of a composition comprising a compound of the formula:



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating basal cell cancer, said medicament mitigating hERG activity while inhibiting growth of the basal cell cancer in a subject.

2. The use of claim 1, wherein the basal cell cancer comprises a constitutively active hedgehog pathway.
3. The use of claim 1 or 2, wherein the cancer is metastatic.
4. The use of any one of claims 1 to 3, wherein multiple cycles of treatment are to be administered to the subject for a time period sufficient to effect at least a partial tumor response.
5. The use of claim 4, wherein the time period is at least 6 months.
6. The use of claim 4, wherein the time period is at least 12 months.
7. The use of any one of claims 4 to 6, wherein multiple cycles of treatment are to be administered to the subject for a time period sufficient to effect a complete tumor response.
8. The use of any one of claims 4 to 7, wherein the medicament is to be administered to the subject according to a daily dosing regimen or intermittently.
9. The use of any one of claims 1 to 8, wherein an additional anti-cancer therapy is to be administered to the subject.

10. The use of claim 9, wherein the additional anti-cancer therapy is surgery, chemotherapy, radiation therapy, immunotherapy, biologic therapy, or a combination thereof.

11. The use of any one of claims 1 to 10, wherein the medicament further comprises a pharmaceutically acceptable excipient.

12. The use of any one of claims 1 to 11, wherein a histone deacetylase (HDAC) inhibitor is to be further administered to the subject.

13. The use of claim 12, wherein the HDAC inhibitor is vorinostat.

14. The use of any one of claims 1 to 13, wherein the subject is mammalian.


15. The use of claim 14, wherein the subject is human.

16. The use of any one of claims 1 to 15, wherein the medicament is to be administered in an amount sufficient to reduce viability of hedgehog pathway-dependent cancerous basal cells in the subject.

17. The use of any one of claims 1 to 16, wherein the medicament is to be administered in an amount sufficient to reduce production of Gli 1 mRNA in cancerous basal cells in the subject.

18. The use of any one of claims 1 to 17, wherein the medicament is to be administered in an amount sufficient to reduce growth and cell proliferation of hedgehog pathway-dependent cancerous basal cells in the subject.

19. A composition comprising a compound of the formula:



or a pharmaceutically acceptable salt thereof, for use in the treatment of basal cell carcinoma (BCC), said composition further comprising a histone deacetylase (HDAC) inhibitor, wherein the HDAC inhibitor is vorinostat.